Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
IL Pharma Inc.
ClinicalTrials.gov Identifier:
NCT01506154
First received: January 5, 2012
Last updated: October 24, 2012
Last verified: October 2012

January 5, 2012
October 24, 2012
December 2011
October 2012   (final data collection date for primary outcome measure)
Mean of all 16 Current Pain Intensity scores collected on Days 4 through 7 on a 0-10 NPRS. [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01506154 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Topical Patch in the Treatment of Pain Due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of Shoulder

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Pain due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of the Shoulder.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Bursitis
  • Tendonitis
  • Shoulder Pain
Drug: MRX-7EAT
Once daily application of a patch for 14 days
  • Placebo Comparator: Placebo
    Therapy with placebo
    Intervention: Drug: MRX-7EAT
  • Experimental: MRX-7EAT
    Therapy with experimental drug
    Intervention: Drug: MRX-7EAT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
210
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Females of child bearing potential must have a negative pregnancy test and be using an adequate method of birth control.
  • Subject has a diagnosis of acute supraspinatous or subacromial bursitis/tendonitis and/or subdeltoid bursitis of one shoulder with the onset of the current episode ≥ 24 hours and ≤ 7 days preceding the screening visit.
  • Subject has a Current Pain Intensity rated prior to study entry ≥ 6 but ≤ 8 on a Numeric Pain Rating Scale (NPRS).

Exclusion Criteria:

  • Subject has a suspected tear in the rotator cuff, calcific tendonitis, adhesive capsulitis, shoulder fractures, bilateral shoulder pain, bilateral tendonitis and/or bursitis of the shoulders, bicipital tendonitis; or orthopedic surgical treatment is required.
  • Subject has a positive Drop Arm Test indicative of a suspected tear; a positive O'Brien's Test suggestive of a glenoid labral tear; a positive Apprehension Test which would be indicative of glenohumeral instability; a positive Yergason's Test which would be indicative of bicipital tendonitis.
  • Subject had a previous episode of shoulder pain in the same area within two weeks prior to the current episode; history of chronic pain in the target shoulder; history of rotator cuff injury or previous surgery in the same area.
  • Subject received passive physical therapy treatments for the pain in the target shoulder within the past 24 hours.
  • Subject has used oral pharmacologic treatment less than 5 half-lives before the baseline assessments.
  • Subject has used any form of opioid within 24 hours of study entry or use of opioids for 5 or more consecutive days within the 30 days preceding enrollment.
  • Subject has received systemic corticosteroids in the 30 days preceding the screening visit; or local injections such as intra-articular, bursal, peritendinous; topical corticosteroids are acceptable unless applied to the target joint; and inhaled or intranasal steroids acceptable (e.g., Flonase®).
  • Subject recently initiated sleep medications, muscle relaxants, anticonvulsants or antidepressants (within the past 30 days).
  • Subject used TNF alpha blockers or Class 1 anti-arrhythmic drugs within the past 60 days.
  • Subject has a history or physical assessment finding of clinically significant GI ulcers or abnormal bleeding, anemia, kidney disease, liver disease, poorly controlled lung, stomach, heart, or other vital organ disease as determined by the study investigator/physician.
  • Subject has fibromyalgia, spondyloarthropathies (SpA) or other systemic arthritis such as rheumatoid arthritis. Arthritis typically localized such as gout or osteoarthritis is acceptable as long as it does not affect the injured area.
  • Subject has a painful syndrome (e.g. sciatica) or cervical spine disorder leading to a nerve entrapment syndrome or other medical problem that in the investigator's opinion may interfere with pain measurement of the target joint.
  • Subject has active skin lesions or disease at the intended site of study medication application, which may be covered by the patch. Skin lesions include open wounds, rash, papules and vesicles; abrasions, lacerations or any break in skin.
  • Subject has a history of allergy to etodolac, other NSAIDs, lidocaine or adhesives (e.g., adhesive tape).
  • Subject is scheduled for elective surgery or other invasive procedures during the period of study participation.
Both
14 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01506154
MRX-7EAT-2006
No
IL Pharma Inc.
IL Pharma Inc.
Not Provided
Study Chair: Yuji Kuwabara IL Pharma
IL Pharma Inc.
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP